ProfileGDS5678 / 1428144_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 75% 72% 79% 76% 74% 73% 74% 73% 73% 73% 73% 72% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7803674
GSM967853U87-EV human glioblastoma xenograft - Control 25.0280975
GSM967854U87-EV human glioblastoma xenograft - Control 34.6443172
GSM967855U87-EV human glioblastoma xenograft - Control 45.6627479
GSM967856U87-EV human glioblastoma xenograft - Control 55.1039576
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7568174
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6087973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7575474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7193773
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6755973
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.720673
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7477273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5857472
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7642174